Skip to main content

Table 4 The relation between the 2 anti P. aeruginosa β-lactamines capable of generating a mutation (ceftazidime and meropenem) and the different acquired resistance mechanisms

From: Risk factors and the resistance mechanisms involved in Pseudomonas aeruginosa mutation in critically ill patients

Acquired resistance mechanisms Ceftazidime after P. aeruginosa Meropenem after P. aeruginosa
no yes p no yes p
Impermeability
no/yes
108 (94.7%) / 6 (5.3%) 38 (97.4%) / 1 (2.6%) 0.679 93 (98.9%) / 1 (1.1%) 53 (89.8%) / 6 (10.2%) 0.0135*
Over-expression of efflux
no/yes
108 (94.7%) / 6 (5.3%) 37 (94.9%) / 2 (5.1%) 0.999 92 (97.9%) / 2 (2.1%) 53 (89.8%) / 6 (10.2%) 0.055
Penicillinase and/or efflux
no/yes
111 (97.4%) / 3 (2.6%) 38 (97.4%) / 1 (2.6%) 0.999 92 (97.9%) / 2 (2.1%) 57 (96.6%) / 2 (3.4%) 0.640
AmpC over-expression
no/yes
105 (92.1%) / 9 (7.9%) 30 (76.9%) / 9 (23.1%) 0.019* 84 (89.4%) / 10 (10.6%) 51 (86.4%) / 8 (13.6%) 0.613
Impermeability +/- Over-production of efflux
no/yes
113 (99.1%) / 1 (0.9%) 37 (94.9%) / 2 (5.1%) 0.160 93 (98.9%) / 1 (1.1%) 57 (96.6%) / 2 (3.4%) 0.559
  1. * signify that it is considered to be statistically significant with p < 0.05